Meanwhile, AKT1, MYC, HSP90AA1, HIF1A, ESR1, TP53, and STAT3 are the potential therapeutic targets of LGZGD in treating NAFLD. This evidence concerns the gene HSP90AA1 and metabolic dysfunction-associated steatotic liver disease.